Molln

Researchers are conducting a prospective, non-interventional observational study to evaluate the long-term effects of dupilumab treatment in patients aged 6 years and older with atopic dermatitis (AD). The study aims to understand the characteristics of AD patients in Germany who receive dupilumab under everyday conditions, including their medical history, socio-demographic and disease-related features, associated atopic comorbidities and type 2 inflammation diseases, as well as their previous and ongoing AD treatments. The study will also assess therapeutic response rates at Month 6 and long-term efficacy at Months 12 and 24 by measuring disease control with tools such as the Atopic Dermatitis Control Tool (ADCT) and Recap of Atopic Eczema (RECAP). Additionally, the study will observe dosing patterns, reasons for treatment changes, and collect long-term safety data. Participants will receive dupilumab treatment as part of their routine care without any intervention from the study. The observation period for each participant lasts up to 2 years or until dupilumab treatment is discontinued. Visits will be scheduled according to the standard of care, and the study will collect data on variations in dosing regimens, treatment initiation or discontinuation reasons, and concomitant therapies. During the study, participants or their guardians will complete questionnaires to assess signs, symptoms, quality of life, and disease control related to atopic dermatitis. Researchers will monitor outcomes such as the number of patients maintaining controlled disease states between Months 6 and 12, and changes in ADCT and RECAP scores over 52 weeks. Safety data will also be collected throughout the observation period to evaluate the long-term effects of dupilumab in both adult and pediatric patients.

Psoriasis is a chronic inflammatory disease that causes thick, red, and white scaly patches on the skin. This research evaluates how treatment with risankizumab affects the quality of life for adults with moderate to severe plaque psoriasis in real-world clinical settings. The study involves about 700 participants who are prescribed risankizumab by their doctors following local guidelines. Participants will receive risankizumab as directed by their physicians according to routine clinical practice and local prescribing information. There are no additional treatments or interventions beyond what is normally prescribed. The study follows participants for up to 2.5 years, with regular visits at hospitals or clinics based on their usual care schedules. During the study, participants will attend routine visits without extra burden. Researchers will monitor changes in quality of life using the Dermatology Life Quality Index (DLQI) at 12 months and observe the long-term impact of risankizumab treatment. Safety and treatment adherence will also be tracked throughout the study period.